 |
|
|
| |
Bemnifosbuvir and ruzasvir are potent HCV DAAs with favorable
antiviral profiles against major HCV NS5A and NS5B RAVs supporting use in combination
|
| |
| |
AASLD 2023 nov 10-14
https://www.aasld.org/the-liver-meeting
Qi Huang, Steven S. Good, Dawei Cai, Nancy G.B. Agrawal, Jean-Pierre Sommadossi
Atea Pharmaceuticals, Boston, MA, US
|
| |
|
|
|
|
|
